{
    "clinical_study": {
        "@rank": "142777", 
        "arm_group": [
            {
                "arm_group_label": "Healthy", 
                "description": "Subjects deemed to be medically healthy"
            }, 
            {
                "arm_group_label": "Obese", 
                "description": "Subjects deemed to be medically obese"
            }
        ], 
        "brief_summary": {
            "textblock": "To examine the influence of obesity on brain activation during food cue, stress, and neutral\n      relaxing conditions"
        }, 
        "brief_title": "fMRI of Stress in Obesity", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "detailed_description": {
            "textblock": "Subjects will participate in an fMRI session to examine changes in frontal and limbic brain\n      regions with food cues, stress and neutral/relaxing imagery"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Between ages 18-50 years old.\n\n          2. Able to read and write.\n\n          3. negative urine toxicology screens during intake appointments indicating no history of\n             current or past dependence on alcohol or illicit drug use.\n\n          4. WOMEN: have a regular menstrual cycle.\n\n          5. BMI:   30 < BMI < 35 for obese subjects (upper limit of 35 selected given our\n             experience with heavier individuals fitting comfortably in the fMRI scanner) and 18.5\n             < BMI <25 for normal weight subjects (Institute, 2006)\n\n        Exclusion Criteria:\n\n          1. any major neurological illness or injury and any current or prior clinically\n             significant mental health (including PTSD) or substance use disorder (with exception\n             of nicotine dependence) as determined by SCID interview;\n\n          2. Regular use of any psychoactive drugs including anxiolytics and antidepressants.\n\n          3. Any significant current medical condition such as neurological, cardiovascular,\n             endocrine, renal, liver, thyroid pathology; subjects on medications for any medical\n             condition will be excluded.\n\n          4. Any subjects with foreign ferromagnetic metal objects in their body or other MR\n             contraindications will be excluded including subjects who work as welders.\n\n          5. Women on oral contraceptives, peri- and post-menopausal women, and pregnant or\n             lactating women (as alterations in stress response are associated with these states)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "30 obese subjects and 30 matched healthy controls will be recruited for this study."
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01719484", 
            "org_study_id": "0805003899"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06519"
                }, 
                "name": "Yale University School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Functional Magnetic Resonance Imaging of Stress in Obesity", 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Marc N Potenza, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "No outcome measures for this study, this is an imaging study only", 
            "safety_issue": "No", 
            "time_frame": "Upon study completion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01719484"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yale University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2008", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}